Featured, News, Trade Ideas

Pioneering B-TRAN Technology to Expand Applications in EVs, Renewable Energy, and Data Centers

December 4, 2024 No comments yet

Ideal Power (IPWR) has announced a significant milestone in its commercialization journey with a multi-unit order for its SymCool IQ intelligent power module. The order comes from a customer specializing in circuit protection and power conversion solutions, marking a promising expansion of Ideal Power’s market reach.

The customer, already familiar with Ideal Power’s SymCool power modules and drivers, is exploring SymCool and SymCool IQ modules for applications in solid-state circuit protection and power conversion across sectors such as electric vehicles (EVs), EV charging, renewable energy, and data centers.

“This multi-unit order for our SymCool IQ is a significant milestone in the commercialization of our B-TRAN technology,” stated Dan Brdar, CEO of Ideal Power. “SymCool IQ opens up additional markets for us, including renewable energy, energy storage, and EV charging. This customer is evaluating SymCool IQ for use in pairing renewable energy with energy storage to leverage the improved efficiency and bidirectionality of our technology.”

The SymCool IQ module builds on Ideal Power’s innovative B-TRAN multi-die packaging with an integrated intelligent driver optimized for bidirectional operation. Rated at 1200V and 200A, SymCool IQ outperforms traditional IGBT modules by offering lower losses, inherent bidirectionality, and reduced thermal management requirements. These advantages lead to increased energy savings, lower operating costs, and compact, cost-effective solutions for OEMs.

Additionally, SymCool IQ includes protection features such as overcurrent and undervoltage protection, along with temperature sensing. Its standard 62-millimeter package makes it a versatile choice for industrial power semiconductor applications.

With this order, Ideal Power is poised to deepen its presence in transformative sectors like renewable energy and EV infrastructure, signaling strong momentum for its patented B-TRAN technology.

Read original press release here

You might like this article: Telomir Pharmaceuticals Announces Breakthrough in Type 2 Diabetes Treatment with Telomir-1

Leave a Reply

Your email address will not be published. Required fields are marked *

Continue reading

Featured, News, Trade Ideas

FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity

March 3, 2025 No comments yet

BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration (FDA) has officially closed its inspection of a single site involved in the TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3). The FDA’s designation of “Voluntary Action Indicated” (VAI) signals that while minor issues may have been identified, no regulatory action is required, further […]

Featured, News, Trade Ideas

Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine

February 20, 2025 No comments yet

Telomir Pharmaceuticals (NASDAQ: TELO) has achieved a major scientific breakthrough by stabilizing Silver(II) (Ag²⁺) using its proprietary compound, Telomir-1. This advancement overcomes a key challenge in silver-based medicine, unlocking new possibilities for antimicrobial treatments, wound care, and infection-resistant medical coatings. Silver(II) offers superior antibacterial action, faster wound healing, and immune-modulating properties compared to traditional Silver(I) […]

Featured, News, Trade Ideas

flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

February 14, 2025 No comments yet

flyExclusive (NYSE American: FLYX), a leading provider of premium jet charter experiences, has entered into a definitive agreement to acquire the aviation business of Jet.AI (NASDAQ: JTAI). The deal will allow flyExclusive to expand its fleet and market presence while enabling Jet.AI to transition into a pure-play AI solutions company. Under the terms of the […]